-
Speedy review for BMS’ Opdivo in colorectal cancers
pharmatimes
April 07, 2017
The US Food and Drug Administration will undertake a priority review of Bristol-Myers Squibb’s immunotherapy Opdivo as ...
-
ICR scientists uncover information about genetic causes of brain cancer
pharmaceutical-technology
March 29, 2017
A new brain cancer study conducted by scientists at London's Institute of Cancer Research (ICR) has revealed new secrets about the genetic causes of the disease.
-
A computer program for diagnosing and locating cancer
biospectrumasia
March 28, 2017
A computer program has been developed by a team of researchers at the University of California for detecting and identifying the location of cancer within the patient's body.
-
Merck and Pfizer secure US FDA approval for Bavencio to treat skin cancer
pharmaceutical-technology
March 28, 2017
Merck’s biopharmaceutical business EMD Serono and Pfizer have obtained the US Food and Drug Administration’s (FDA) approval for a?20mg/mL Bavencio (avelumab) injection to treat ...
-
Leukaemia CARE’s research finds inequalities in cancer care for elderly patients
pharmaceutical-technology
March 28, 2017
UK charity Leukaemia CARE has conducted new research into the lives of older people living with blood cancers and revealed inequalities in cancer care for elderly patients compared with ...
-
Contraceptive pill reduces cancer risk long-term, study finds
pharmatimes
March 23, 2017
Women who have taken the oral contraceptives seem have a reduced risk of developing some types of cancer for as ...
-
Ferrier Research Institute and BCFNZ to create new breast cancer vaccine
pharmaceutical-technology
March 23, 2017
Victoria University of Wellington's Ferrier Research Institute and the Breast Cancer Foundation New Zealand (BCFNZ) ...
-
Pierre Fabre and H-Immune to develop new cancer immunotherapies
pharmaceutical-technology
March 23, 2017
French pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop ...
-
BMS, CytomX Expand Probody Pact
contractpharma
March 21, 2017
BMS gains worldwide rights to develop and commercialize as many as six additional oncology targets
-
NICE rejects use of daratumumab (darzalex) monotherapy for treatment of myeloma
pharmaceutical-technology
March 21, 2017
he UK National Institute for Health and Care Excellence (NICE) has issued draft negative guidance on anti-cancer drug...
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
